english.prescrire.org > Spotlight > 100 most recent > Belimumab (Benlysta°) in lupus nephritis

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Belimumab (Benlysta°) in lupus nephritis

  Marketing Authorisations  Belimumab, a monoclonal antibody directed against a protein called BLyS (B lymphocyte stimulator), was initially authorised in the European Union for subcutaneous or intravenous use in systemic lupus erythematosus. It has now also been authorised for use in active lupus nephritis.

Its evaluation in this situation is based on a single double-blind randomised trial of intravenous belimumab versus placebo, added to other immunosuppressants (including a corticosteroid, mycophenolate mofetil and cyclophosphamide). The 2-year trial included 448 adults, 84% of whom had active lupus nephritis class III to V...

©Prescrire 1 April 2023

Source: "Belimumab (Benlysta°) in lupus nephritis" Prescrire International 2023; 32 (247): 96. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >